Amylyx Pharma Q2 2024 Adj. EPS $(0.73), Inline,
Portfolio Pulse from Benzinga Newsdesk
Amylyx Pharma (NASDAQ:AMLX) reported Q2 2024 adjusted EPS of $(0.73), which met analyst expectations. However, the company reported quarterly sales of $(1.203 million), significantly missing the analyst consensus estimate of $10.663 million and representing a 101.22% decrease from the same period last year.
August 08, 2024 | 11:15 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Amylyx Pharma reported Q2 2024 adjusted EPS of $(0.73), meeting analyst expectations. However, the company significantly missed sales estimates, reporting $(1.203 million) against the expected $10.663 million, a 101.22% decrease from the previous year.
While Amylyx Pharma's EPS met expectations, the significant miss in sales and the drastic year-over-year decrease in revenue are likely to negatively impact the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100